More News

Our integrated and personalised approach

neuroCare provides drug free, side-effect free and sustainable outcomes in therapy for ADHD, depression, chronic pain and for rehabilitation. At our neuroCare clinics we achieve this by integrating the work of clinicians with leading neuromodulation technology and by personalising the therapy. neuroConn is our technology brand, a global leader and industry pioneer in non-invasive neuromodulation. At neuroCademy we educate clinicians about neuromodulation and how to apply it in clinical practice and we evaluate outcomes and do research to further the quality of our care delivery.

Everything we do, think or feel is a memorised pattern in our brain or muscle memory. By harnessing the human brain’s plasticity, neuromodulation helps to reprogram those patterns by training our mind to more positive behaviour or for better cognitive performance. Behavourial, cognitive or motor disturbances can be treated faster and more efficiently when neurotechnology and the therapist work in synergy. Our integrated and personalised approach shows an efficacy of up to 76% for patients with ADHD and an efficacy of up to 78% for patients with depression - something we are truly proud of.

At neuroCare, we also apply neurotechnologies in the diagnosis of mental disorders, allowing the therapist to personalise the treatment to the patient’s individual need - this is called prognostics.​​ Most current treatments in mental health or neurology, particularly psychopharmaceuticals, still rely on a one-size-fits-all approach. Individual differences are ignored even though not all patients have the same underlying cause for their symptoms. This is why neuroCare has become a leader in the fast-growing neurotherapy market.​

Introduction to the neuroCare Group